Pharmaceutical

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

Sep 23, 2023 - 20:00
Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate
According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.
Read the original article

Tags:

Previous Article

Over half of world’s population not covered by essential healthcare services

Next Article

JURA Bio and Syena partner to develop TCR-based therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Sanofi’s $17bn sale of Opella to US investors advances ...

Oct 22, 2024

FDA grants fast track status to FELIQS’s FLQ-101 to prevent ROP

FDA grants fast track status to FELIQS’s FLQ-101 to pre...

Nov 5, 2024

Can reforms restore faith in India’s pharma industry after cough syrup scandals?

Can reforms restore faith in India’s pharma industry af...

Sep 29, 2023